Newsfeeds - Spark Newswire

4 minute read

51 Biggest Movers From Yesterday

Today, 7:50 AM

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.

ALLG

2 minute read

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 7:50 AM

BBLG

2 minute read

18 Stocks Moving in Tuesday’s Pre-Market Session

By Lisa Levin

Today, 7:50 AM

Gainers System1, Inc. (NYSE: SST) rose 37.5% to $22.70 in pre-market trading as the company reported a 48% year-over-year surge in Q4 sales and issued strong sales forecast.

ANY

1 minute read

Hot
News

‘Arcus Biosciences Set to Join S&P SmallCap 600,’ Replacing Investors Bancorp -S&P Dow Jones Indices

By Benzinga Newsdesk

Today, 7:50 AM

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20220404-1451281/1451281_isbc6.pdf

CFG

1 minute read

Earnings

Recap: Arcus Biosciences Q4 Earnings

By Benzinga Insights

Today, 7:50 AM

Arcus Biosciences (NYSE:RCUS) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:10 PM. Here's what investors need to know about the announcement.

RCUS

1 minute read

Arcus Biosciences Q4 EPS $3.71 Up From $(0.82) YoY, Sales $354.50M Up From $9.49M YoY

By Benzinga Newsdesk

Today, 7:50 AM

Arcus Biosciences (NYSE:RCUS) reported quarterly earnings of $3.71 per share. This is a 552.44 percent increase over losses of $(0.82) per share from the same period last year. The company reported $354.50 million in

RCUS

15 minute read

Earnings Scheduled For February 23, 2022

By Benzinga Insights

Today, 7:50 AM

Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.

AAN

1 minute read

Earnings

Arcus Biosciences’s Earnings: A Preview

By Benzinga Insights

Today, 7:50 AM

Arcus Biosciences (NYSE:RCUS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement. Analysts estimate that Arcus Biosciences will report an earnings per share (EPS) of $-0.74.

RCUS

1 minute read

News

Arcus Biosciences Granted U.S. Patent #11,220,492 ‘Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders’

By Charles Gross

Today, 7:50 AM

View Patent here

RCUS

1 minute read

FDA
News

Gilead, Arcus Biosciences Complete Closing Of Option Exercise For 3 Clinical-Stage Programs And New Research Collaboration

By Benzinga Newsdesk

Today, 7:50 AM

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced the closing of Gilead's option exercises to three programs in Arcus' clinical-stage portfolio and a new research

GILD